Free Online CME

Rheumatoid Arthritis:
Improving Treatment Decisions and Quality of Care in
Clinical Practice

Rheumatoid Arthritis: Improving Treatment Decisions and Quality of Care in Clinical Practice is a 3-part CME case series on the emerging concepts of achieving tight control of RA and treating to target have been well established and utilize early diagnosis, aggressive treatment, and regular monitoring.

 

This series has expired. Please go to our Rheumatology/Immunology home page to find related content.

Series Objectives

  1. Describe updates from the European League Against Rheumatism (EULAR) and the forthcoming American College of Rheumatology (ACR) guidelines, and apply appropriate new recommendations into clinical practice
  2. Employ the "treat-to-target" approach to rheumatoid arthritis (RA) management via incorporation of routine use of validated composite disease-activity measures, biomarkers, and instruments
  3. Compare and contrast efficacy, safety, and tolerability of available biologic agents used in the presence of disease and patient-related variables, such as comorbidities, risk tolerance, and dosing convenience
  4. Utilize effective communication and education to engage RA patients in shared decision-making on treatment choices

Target Audience

These activities are directed to rheumatologists, internal medicine physicians, nurse practitioners, physician assistants, and other health care professionals caring for patients with immunologic diseases.

Activity Director

Leonard H. Calabrese, DO
Professor of Medicine, Cleveland Clinic
Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Orthopaedic & Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Planning Committee

Elizabeth Kirchner, MSN
Department of Rheumatic and Immunologic Diseases
Cleveland Clinic
Cleveland, OH

This CME activity was produced by Cleveland Clinic Center for Continuing Education,
R.J. Fasenmyer Center for Clinical Immunology and Haymarket Medical Education.